Latest Safety News

Chimeric Therapeutics reports encouraging Phase 1B data from its ADVENT-AML trial, showing safety and multiple complete responses in high-risk AML patients treated with CORE-NK combined with standard therapies.

AKORA Resources has initiated a surface trenching program at its Bekisopa Iron Ore Project in Madagascar, aiming to extend its high-grade direct shipping ore resource despite ongoing local unrest. The company remains confident in project progress and safety.

dorsaVi has confirmed its RRAM Reflex Platform achieves biological-grade reflexes with sub-microsecond latency and ultra-low energy use, outperforming leading digital edge AI systems by orders of magnitude.

Radiopharm Theranostics has received a positive safety recommendation to increase the dose of its radiotherapeutic 177Lu-RAD202 in the Phase 1 HEAT trial for HER2-positive advanced solid tumors, signaling promising early results.

Austral Gold has lowered its 2025 production forecast for the Guanaco Mine following a workplace fatality that halted key processing operations. The company has also sold equity holdings to bolster cash flow amid operational disruptions.

OD6 Metals has selected an innovative process flowsheet for its Splinter Rock Rare Earth Project, achieving approximately 75% recovery of key rare earths with superior product purity and optimized costs. This milestone sets the stage for advanced testing and mining studies as the company advances toward production.

Savannah Goldfields is on track to resume gold production at its Georgetown Gold Project by the end of October, with key maintenance and environmental approvals completed.

TerraCom Limited reports a $43.4 million net loss for FY25, reflecting increased impairment charges and operational challenges, while advancing its strategic Moorlands Project in Australia.

Altech Batteries has partnered with AMPower to immediately market and distribute sodium nickel chloride batteries across Europe, Australia, and the USA, fast-tracking revenue ahead of its large-scale CERENERGY project in Germany.

Paradigm Biopharmaceuticals has dosed participants in its pivotal Phase 3 trial for knee osteoarthritis across the US and Australia, progressing steadily towards a mid-2026 interim analysis.

Lakes Blue Energy has wrapped up drilling at its Wombat-5 well in Victoria’s Gippsland Basin, setting the stage for critical gas flow testing to assess commercial potential.

Starpharma has entered a strategic research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset using its proprietary dendrimer technology, unlocking potential milestone payments of up to AUD $89 million.